Eli Lilly and Almirall report promising results from phase III atopic eczema study
A collaboration between Spanish firm Almirall and US-based Eli Lilly has so far resulted in positive results from three of five global phase III studies with the drug lebrikizumab. Marketing rights for Europe and the rest of the world have been split between the firms.
by ulrich quistgaard, translated by daniel pedersen
Pharmaceutical giant Eli Lilly and Spanish dermatology company Almirall have come together to develop a treatment for atopic dermatitis, also known as atopic eczema.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
England and Wales reject Leo Pharma's eczema drug
For subscribers
